Oncology Nursing News®

Immuno-Oncology

KATE2 Study Misses Endpoint, Appears Promising for HER2+, PD-L1-Expressing Breast Tumors

KATE2 Study Misses Endpoint, Appears Promising for HER2+, PD-L1-Expressing Breast Tumors

BY CONOR KILLMURRAY

Utilizing Immunotherapy To Treat Patients With Early Breast Cancer

Utilizing Immunotherapy To Treat Patients With Early Breast Cancer

BY CONOR KILLMURRAY

Expert Weighs in on Treating Early-Stage Breast Cancer With Immunotherapy

Expert Weighs in on Treating Early-Stage Breast Cancer With Immunotherapy

BY REBECCA DENT, MD

ONN's Top 5 Stories: September 2019

ONN's Top 5 Stories: September 2019

BY JESSICA SKARZYNSKI

Expert Discusses Immunotherapy-Related Myocarditis

Expert Discusses Immunotherapy-Related Myocarditis

BY BRIELLE BENYON

Immunotherapy Combo Is Promising in MSI-H Colorectal Cancer

Immunotherapy Combo Is Promising in MSI-H Colorectal Cancer

BY KRISTI ROSA

Patients Rely on Nurses for Crucial Immunotherapy Information

Patients Rely on Nurses for Crucial Immunotherapy Information

BY GRACE CHERRY, NP, MSN, RN

More Is Needed for Immunotherapy in Lung Cancer

More Is Needed for Immunotherapy in Lung Cancer

BY FRED R. HIRSCH, MD, PHD

Gut Microbiome Can Impact Immunotherapy Response

Gut Microbiome Can Impact Immunotherapy Response

BY BRIELLE BENYON

Managing Skin Toxicity From Treatment With Checkpoint Inhibitors in NSCLC

Managing Skin Toxicity From Treatment With Checkpoint Inhibitors in NSCLC

BY KATIE KOSKO

External Resources

MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
TargetedOnc

OncNurse Resources

Newsroom
Continuing Education
Discussions
Web Exclusives

About Us
Advertise
Advisory Board
Careers
Contact Us
Privacy Policy
Terms & Conditions

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2019
Intellisphere, LLC. All Rights Reserved.